Insmed Incorporated (INSM)
INSM trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1104506/000110450626000009/0001104506-26-000009-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | INSM on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001104506 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | VA |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $606.4M |
| Net income | -$1.3B |
| Operating income | -$1.2B |
| Net margin | -210.5% |
| Operating margin | -205.6% |
| Revenue growth | +66.7% |
| Cash | $510.4M |
| Total assets | $2.3B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 44.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-29 |
| Cash and burn | $396.6M cash; operating cash flow -$148.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 219,380,309 (2026-10-23); 213,273,469 a year earlier; 143,062,065 three years earlier. | Cover page 2026-10-23 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-05-15 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Iselin, New Jersey, United States | PCAOB Form AP 2026-03-02 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $167.1M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $524.4M | -$100.3M | -$36.5M | $396.6M | $546.8M | $1.5B | 10-Q 2026-10-29 |
| Q2 2026 2026-06-30 | $425.5M | -$13.2M | -$88.8M | $544.8M | $546.8M | $1.1B | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $306.0M | -$163.6M | -$222.7M | $582.2M | $546.8M | $819.6M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $263.8M | -$328.5M | -$247.6M | $510.4M | $546.8M | $606.4M | 10-K 2026-02-19 |
| Q3 2025 2025-09-30 | $142.3M | -$370.0M | -$219.8M | $334.8M | $546.8M | $447.0M | 10-Q 2026-10-29 |
| Q2 2025 2025-06-30 | $107.4M | -$321.7M | -$205.6M | $1.3B | $546.8M | $398.1M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $92.8M | -$256.6M | -$262.1M | $403.2M | $1.1B | $381.0M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $104.4M | -$235.5M | -$196.0M | $555.0M | $1.1B | $363.7M | 10-K 2026-02-19 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-05-15 |
| Latest annual report | 10-K | 2026-02-19 |
| Latest quarterly / interim | 10-Q | 2026-10-29 |
| Latest current report | 8-K | 2026-10-29 |
| Latest proxy | DEFA14A | 2026-04-01 |
Source: SEC EDGAR submissions feed, 1,011 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +5.9% |
| 1 month | +25.2% |
| 3 months | -4.1% |
| Year to date | -30.4% |
| 1 year | -36.6% |
| From 52-week high | -42.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ROIV | Roivant Sciences Ltd. Common Shares | $38.61 | -2.33% | $28.0B |
| UTHR | United Therapeutics Corporation | $587.88 | -0.56% | $25.0B |
| VTRS | Viatris Inc. | $20.74 | -0.38% | $23.8B |
| GMAB | Genmab A/S ADS | $51.57 | +0.39% | $32.2B |
| ALNY | Alnylam Pharmaceuticals Inc. | $159.73 | -3.22% | $21.4B |
| ZTS | Zoetis Inc. | $84.39 | +0.68% | $34.3B |
| RPRX | Royalty Pharma plc Class A Ordinary Shares | $68.53 | -1.13% | $39.3B |
| ASND | Ascendis Pharma A/S Ordinary Share | $271.73 | -1.33% | $17.9B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier